The therapy is a bispecific antibody about to enter phase 2 studies targeting atopic dermatitis, a common inflammatory skin disease. Pending regulatory approval, J&J expects to acquire the drug candidate from Switzerland-based Numab Therapeutics in the second half of 2024.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
